K243863 is an FDA 510(k) clearance for the Opulus™ Lymphoma Precision. Classified as Automated Radiological Image Processing Software within the QIH classification (a category dominated by AI-based automated radiology processing systems), Class II - Special Controls.
Submitted by Roche Molecular Systems, Inc. (Santa Clara, US). The FDA issued a Cleared decision on May 30, 2025 after a review of 164 days - an extended review cycle.
This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.2050 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Incremental AI imaging tool. Moderate equivalence dependency. Overall, this clearance reflects a predicate-aligned approval typical of modern AI radiology extensions - not a novel clinical breakthrough, but a validated iteration within an established regulatory category.
View all Roche Molecular Systems, Inc. devices